CytoSorbents 2025 revenue rises, net loss narrows

Reuters

Mar 26

CytoSorbents 2025 revenue rises, net loss narrows

Overview

U.S. blood purification device maker's 2025 revenue grew 4%, flat on constant currency
Company implemented workforce and cost reduction program in Q4
Secured $2.5 mln additional liquidity through amended credit facility in November

Outlook

CytoSorbents expects to achieve cash flow breakeven in the second half of 2026
CytoSorbents expects incremental improvement in commercial activity across 2026

Result Drivers

GERMAN SALES DECLINE - Co said 10% drop in Germany annual sales reflected restructuring of sales operations and new strategies
COST REDUCTION - Co implemented workforce and cost reduction program in Q4 to lower expenses and accelerate cash flow breakeven

Company press release: ID:nPnc7zYJHa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
FY EPS		-$0.13

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Cytosorbents Corp is $5.00, about 618.6% above its March 24 closing price of $0.70

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2622700239"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622700239\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622700239?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622700239","market":"us","top_or_hot":-1,"title":"CytoSorbents 2025 revenue rises, net loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CytoSorbents 2025 revenue rises, net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>U.S. blood purification device maker's 2025 revenue grew 4%, flat on constant currency</p></li><li><p>Company implemented workforce and cost reduction program in Q4</p></li><li><p>Secured $2.5 mln additional liquidity through amended credit facility in November</p></li></ul><p><span>Outlook</span></p><ul><li><p>CytoSorbents expects to achieve cash flow breakeven in the second half of 2026</p></li><li><p>CytoSorbents expects incremental improvement in commercial activity across 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>GERMAN SALES DECLINE - Co said 10% drop in Germany annual sales reflected restructuring of sales operations and new strategies</p></li><li><p>COST REDUCTION - Co implemented workforce and cost reduction program in Q4 to lower expenses and accelerate cash flow breakeven</p></li></ul><p>Company press release: <span>ID:nPnc7zYJHa</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>FY EPS</p></td><td></td><td><p>-$0.13</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Cytosorbents Corp is $5.00, about 618.6% above its March 24 closing price of $0.70</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CytoSorbents 2025 revenue rises, net loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytoSorbents 2025 revenue rises, net loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 04:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CytoSorbents 2025 revenue rises, net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>U.S. blood purification device maker's 2025 revenue grew 4%, flat on constant currency</p></li><li><p>Company implemented workforce and cost reduction program in Q4</p></li><li><p>Secured $2.5 mln additional liquidity through amended credit facility in November</p></li></ul><p><span>Outlook</span></p><ul><li><p>CytoSorbents expects to achieve cash flow breakeven in the second half of 2026</p></li><li><p>CytoSorbents expects incremental improvement in commercial activity across 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>GERMAN SALES DECLINE - Co said 10% drop in Germany annual sales reflected restructuring of sales operations and new strategies</p></li><li><p>COST REDUCTION - Co implemented workforce and cost reduction program in Q4 to lower expenses and accelerate cash flow breakeven</p></li></ul><p>Company press release: <span>ID:nPnc7zYJHa</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>FY EPS</p></td><td></td><td><p>-$0.13</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Cytosorbents Corp is $5.00, about 618.6% above its March 24 closing price of $0.70</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL1N40D141:1","article_id":"2622700239","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622700239","pubTimestamp":1774470343,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CytoSorbents 2025 revenue rises, net loss narrowsOverviewU.S. blood purification device maker's 2025 revenue grew 4%, flat on constant currencyCompany implemented workforce and cost reduction program ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","CTSO":"Cytosorbents Corporation"},"translate_title":"细胞吸附剂2025年收入增长，净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTSO":0.9},"content_text":"CytoSorbents 2025 revenue rises, net loss narrowsOverviewU.S. blood purification device maker's 2025 revenue grew 4%, flat on constant currencyCompany implemented workforce and cost reduction program in Q4Secured $2.5 mln additional liquidity through amended credit facility in NovemberOutlookCytoSorbents expects to achieve cash flow breakeven in the second half of 2026CytoSorbents expects incremental improvement in commercial activity across 2026Result DriversGERMAN SALES DECLINE - Co said 10% drop in Germany annual sales reflected restructuring of sales operations and new strategiesCOST REDUCTION - Co implemented workforce and cost reduction program in Q4 to lower expenses and accelerate cash flow breakevenCompany press release: ID:nPnc7zYJHaKey DetailsMetricBeat/MissActualConsensus EstimateFY EPS-$0.13Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy\"Wall Street's median 12-month price target for Cytosorbents Corp is $5.00, about 618.6% above its March 24 closing price of $0.70For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}